Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (216) 216
Patent (16) 16
Magazine Article (3) 3
Publication (3) 3
Book / eBook (2) 2
Newspaper Article (2) 2
Book Chapter (1) 1
Book Review (1) 1
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (124) 124
life sciences & biomedicine (119) 119
humans (111) 111
abridged index medicus (59) 59
male (58) 58
female (49) 49
biological and medical sciences (42) 42
medical sciences (39) 39
middle aged (37) 37
cardiovascular system & cardiology (33) 33
cardiac & cardiovascular systems (31) 31
adult (28) 28
general & internal medicine (26) 26
medicine, general & internal (25) 25
pharmacology. drug treatments (23) 23
aged (22) 22
urology & nephrology (21) 21
lovastatin - adverse effects (19) 19
double-blind method (18) 18
hydroxymethylglutaryl-coa reductase inhibitors (18) 18
cholesterol - blood (16) 16
hypercholesterolemia - drug therapy (16) 16
pharmacology & pharmacy (16) 16
simvastatin (16) 16
animals (15) 15
anticholesteremic agents - therapeutic use (15) 15
cholesterol (14) 14
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (14) 14
lovastatin (13) 13
lovastatin - therapeutic use (13) 13
treatment outcome (13) 13
adolescent (12) 12
analysis (12) 12
cholesterol, ldl - blood (12) 12
general and cellular metabolism. vitamins (12) 12
orthopedics (12) 12
statins (12) 12
cardiovascular disease (11) 11
clinical trials as topic (11) 11
dose-response relationship, drug (11) 11
lipids (11) 11
randomized controlled trials as topic (11) 11
urology (11) 11
drug therapy (10) 10
human necessities (10) 10
hygiene (10) 10
incidence (10) 10
medical or veterinary science (10) 10
medical research (10) 10
preparations for medical, dental, or toilet purposes (10) 10
retrospective studies (10) 10
anticholesteremic agents - adverse effects (9) 9
clinical neurology (9) 9
heart (9) 9
mortality (9) 9
neurosciences & neurology (9) 9
care and treatment (8) 8
coronary disease - prevention & control (8) 8
hydroxymethylglutaryl-coa reductase inhibitors - adverse effects (8) 8
lipoproteins (8) 8
risk factors (8) 8
simvastatin - therapeutic use (8) 8
specific therapeutic activity of chemical compounds ormedicinal preparations (8) 8
cancer (7) 7
cardiovascular diseases (7) 7
clinical trials (7) 7
drug therapy, combination (7) 7
follow-up studies (7) 7
health aspects (7) 7
lovastatin - analogs & derivatives (7) 7
research (7) 7
research article (7) 7
time factors (7) 7
triglycerides - blood (7) 7
cardiovascular (6) 6
child (6) 6
dosage and administration (6) 6
drug interactions (6) 6
evaluation (6) 6
infant (6) 6
internal medicine (6) 6
kidney neoplasms - pathology (6) 6
low density lipoproteins (6) 6
muscular diseases - chemically induced (6) 6
surgery (6) 6
tumors (6) 6
cardiovascular diseases - prevention & control (5) 5
cardiovascular system (5) 5
diagnosis (5) 5
drug evaluation (5) 5
ezetimibe (5) 5
health risk assessment (5) 5
heart attacks (5) 5
hypercholesterolemia (5) 5
infant, newborn (5) 5
kidney neoplasms (5) 5
lipoproteins - blood (5) 5
lovastatin - pharmacology (5) 5
low density lipoprotein (5) 5
medicine, experimental (5) 5
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease
by Bowman, Louise and Hopewell, Jemma C and Chen, Fang and Wallendszus, Karl and Stevens, William and Collins, Rory and Wiviott, Stephen D and Cannon, Christopher P and Braunwald, Eugene and Sammons, Emily and Landray, Martin J and The HPS3/TIMI55–REVEAL Collaborative Group and HPS3 TIMI55-REVEAl Collaborative and HPS3/TIMI55–REVEAL Collaborative Group
The New England journal of medicine, ISSN 0028-4793, 09/2017, Volume 377, Issue 13, pp. 1217 - 1227
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Cholesterol Ester Transfer Proteins - antagonists & inhibitors | Atherosclerosis - drug therapy | Double-Blind Method | Cholesterol - blood | Humans | Middle Aged | Kaplan-Meier Estimate | Atherosclerosis - complications | Coronary Disease - epidemiology | Male | Oxazolidinones - adverse effects | Anticholesteremic Agents - adverse effects | Coronary Disease - mortality | Incidence | Oxazolidinones - therapeutic use | Coronary Disease - prevention & control | Medication Adherence | Anticholesteremic Agents - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Female | Aged | Drug Therapy, Combination | Myocardial infarction | Lipoproteins (low density) | Inhibitor drugs | Heart attacks | Clinical trials | Lipids | Low density lipoprotein | Cholesterol | Cholesteryl ester transfer protein | Clinical outcomes | Side effects | Arteriosclerosis | Atherosclerosis | Atorvastatin | Cardiovascular diseases | Health risk assessment | Drug therapy | Lipoproteins (high density) | Cancer | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials
by Cholesterol Treatment Trialists' (CTT) Collaboration and Cholesterol Treatment Trialists and Cholesterol Treatment Trialists’ (CTT) Collaboration and Cholesterol Treatment Trialists' (CTT) Collaboration and Sahlgrenska akademin and Institutionen för medicin, avdelningen för akut och kardiovaskulär medicin and Institute of Medicine, Department of Emergeny and Cardiovascular Medicine and Göteborgs universitet and Gothenburg University and Sahlgrenska Academy
The Lancet (British edition), ISSN 0140-6736, 2010, Volume 376, Issue 9753, pp. 1670 - 1681
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Biological and medical sciences | General aspects | Medical sciences | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Coronary Disease - prevention & control | Stroke - prevention & control | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Humans | Cholesterol, LDL - blood | Myocardial Infarction - prevention & control | Coronary Disease - mortality | Randomized Controlled Trials as Topic | Heart failure | Heart attacks | Report writing | Data collection | Cardiovascular disease | Acute coronary syndromes | Cholesterol | Statins | Meta-analysis | Index Medicus | Abridged Index Medicus | Stroke | MEDICIN OCH HÄLSOVETENSKAP | prevention & control | blood | Myocardial Infarction | Coronary Disease | administration & dosage | LDL | mortality | adverse effects | Hydroxymethylglutaryl-CoA Reductase Inhibitors | MEDICAL AND HEALTH SCIENCES
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials
by Cholesterol Treatment Trialists' (CTT) Collaborators and Cholesterol Treatment Trialists and Cholesterol Treatment Trialists' (CTT) Collaborators
The Lancet (British edition), ISSN 0140-6736, 2012, Volume 380, Issue 9841, pp. 581 - 590
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Public health. Hygiene-occupational medicine | Public health. Hygiene | Biological and medical sciences | General aspects | Miscellaneous | Medical sciences | Risk Assessment - methods | Vascular Diseases - prevention & control | Humans | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Cholesterol, LDL - blood | Treatment Outcome | Vascular Diseases - epidemiology | Vascular Diseases - blood | Practice Guidelines as Topic | Randomized Controlled Trials as Topic | Prevention | Complications and side effects | Low density lipoproteins | Dosage and administration | Cardiovascular diseases | Health aspects | Risk factors | Statins | Medical research | Cardiovascular disease | Heart attacks | Cholesterol | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trials
by Fulcher, Jordan and O'Connell, Rachel and Voysey, Merryn and Emberson, Jonathan and Blackwell, Lisa and Mihaylova, Borislava and Collins, Rory and Kirby, Adrienne and Colhoun, Helen and La Rosa, John and Davis, Barry and Franzosi, Maria Grazia and Baigent, Colin and Keech, Anthony and De Lemos, J and Braunwald, E and Blazing, M and Murphy, S and Holdaas, H and Gordon, D and Davis, B and Koren, M and Poulter, N and Sever, P and Knopp, R.H and Holdaas, H and Jardine, A and Schmieder, R and Zannad, F and Goldbourt, U and Colhoun, H.M and Betteridge, D.J and Durrington, P.N and Fuller, J and Neil, A and Sacks, F and Pfeffer, M and Hawkins, C.M and Braunwald, E and Kjekshus, J and Wedel, H and Wikstrand, J and Barter, P and Tavazzi, L and Bloomfield, H and Robins, S and Collins, R and Parish, S and Peto, R and Sleight, P and Pedersen, T.R and Ridker, P.M and Holman, R and Meade, T and Simes, J and MacMahon, S and Marschner, I and Tonkin, A and Shaw, J and Serruys, P.W and Nakamura, H and Furberg, C and Byington, R and Ford, I and Blauw, G.J and Packard, C and Shepherd, J and Pedersen, T and Wilhelmsen, L and Braunwald, E and Cannon, C and Murphy, S and Collins, R and Armitage, J and Bowman, L and Parish, S and Sleight, P and Baigent, C and Collins, R and Rossouw, J and Probstfield, J and Shepherd, J and Cobbe, S and Macfarlane, P and Ford, I and Flather, M and Kastelein, J and Newman, C and Shear, C and Tobert, J and White, H and Keech, A.C and Marschner, I.C and Simes, J and Baigent, C and Blackwell, L and Collins, R and Emberson, J and Holland, L.E and Reith, C and Cholesterol Treatment Trialists' (CTT) Collaboration and Cholesterol Treatment Trialists' C
The Lancet (British edition), ISSN 0140-6736, 2015, Volume 385, Issue 9976, pp. 1397 - 1405
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Stroke - prevention & control | Cardiovascular Diseases - prevention & control | Humans | Proportional Hazards Models | Male | Treatment Outcome | Coronary Disease - prevention & control | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Sex Factors | Cholesterol, LDL - blood | Female | Percutaneous Coronary Intervention - statistics & numerical data | Databases, Factual | Low density lipoproteins | Analysis | Studies | Heart attacks | Drug therapy | Low density lipoprotein | Cholesterol | Statins | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: Trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment
by Haynes, Richard and Jiang, Lixin and Hopewell, Jemma C and Li, Jing and Chen, Fang and Parish, Sarah and Landray, Martin J and Collins, Rory and Armitage, Jane and Baigent, C and Chen, Z and Chen, Y and Pedersen, T and Bowman, L and Chen, F and Hill, M and Knott, C and Rahimi, K and Tobert, J and Sleight, P and Simpson, D and Baxter, A and Lay, M and Bray, C and Wincott, E and Leijenhorst, G and Skattebol, A and Moen, G and Mitchel, Y and Kuznetsova, O and MacMahon, S and Kjekshus, J and Hill, C and Lam, T.H and Sandercock, P and Peto, R and HPS2-THRIVE Collaborative Grp and HPS2-THRIVE Collaborative Group
European heart journal, ISSN 0195-668X, 05/2013, Volume 34, Issue 17, pp. 1279 - 1291
cardiovascular disease | LDL-cholesterol | ER niacin/laropiprant | secondary prevention | HDL-cholesterol | Cardiac & Cardiovascular Systems | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Hypolipidemic Agents - adverse effects | Stroke - prevention & control | Simvastatin - administration & dosage | Humans | Middle Aged | Myocardial Reperfusion - statistics & numerical data | Death, Sudden, Cardiac - prevention & control | Male | Indoles - administration & dosage | Niacin - administration & dosage | Indoles - adverse effects | Arterial Occlusive Diseases - drug therapy | Hypolipidemic Agents - administration & dosage | Niacin - adverse effects | Female | Myocardial Infarction - prevention & control | Muscular Diseases - chemically induced | Drug Therapy, Combination | Delayed-Action Preparations | Chemical and Drug Induced Liver Injury - etiology | Index Medicus | ER niacin | laropiprant | Fasttrack Clinical
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Dose-dependent effects of folic acid on blood concentrations of homocysteine: a meta-analysis of the randomized trials
by Homocysteine Studies Collab and Homocysteine Lowering Trialists' C and Homocysteine Lowering Trialists' Collaboration and Homocysteine Lowering Trialists’ Collaboration
The American journal of clinical nutrition, ISSN 0002-9165, 2005, Volume 82, Issue 4, pp. 806 - 814
Homocysteine | Randomized trial | Folic acid | Life Sciences & Biomedicine | Nutrition & Dietetics | Science & Technology | Fundamental and applied biological sciences. Psychology | Feeding. Feeding behavior | Biological and medical sciences | Vertebrates: anatomy and physiology, studies on body, several organs or systems | Vitamin B 12 - administration & dosage | Vitamin B 6 - pharmacology | Folic Acid - pharmacology | Humans | Middle Aged | Vitamin B 12 - pharmacology | Homocysteine - blood | Male | Folic Acid - administration & dosage | Vitamin B 6 - administration & dosage | Randomized Controlled Trials as Topic | Dose-Response Relationship, Drug | Drug Synergism | Adolescent | Sex Factors | Aged, 80 and over | Adult | Female | Aged | Dietary Supplements | Clinical trials | Vitamin B | Blood | Dietary supplements | Meta-analysis | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL) – A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: trial design, recruitment and baseline characteristics
by Landray, Martin J and L. Bowman, F. Chen, E. Sammons, J.C. Hopewell, K. Wallendszus, W. Stevens, E. Valdes-Marquez, S. Wiviott, C.P. Cannon, E. Braunwald, R. Collins, M.J. Landray (Writing Committtee) and Reveal Collaborative Group and REVEAL Collaborative Group
The American heart journal, ISSN 0002-8703, 2017, Volume 187, pp. 182 - 190
Cardiovascular | Cardiac & Cardiovascular Systems | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Double-Blind Method | Cholesterol, HDL - drug effects | Humans | Middle Aged | Atorvastatin - therapeutic use | Cholesterol, LDL - drug effects | Male | Oxazolidinones - adverse effects | Anticholesteremic Agents - adverse effects | Oxazolidinones - therapeutic use | Coronary Disease - prevention & control | Anticholesteremic Agents - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Intention to Treat Analysis | Cholesterol, HDL - blood | Cholesterol, LDL - blood | Female | Aged | Drug Therapy, Combination | Research Design | Clinical trials | Medicine, Experimental | Blood circulation disorders | Medical research | Low density lipoproteins | Cardiovascular agents | Coronary heart disease | Epidemiology | Blood cholesterol | Coronary artery bypass | Diabetes | Trans fatty acids | Statins | Myocardial infarction | Lipoproteins (low density) | Evaluation | Diabetes mellitus | Health risks | Lipids | Cardiovascular disease | Low density lipoprotein | Coronary artery disease | Cholesterol | Cholesteryl ester transfer protein | Recruitment | Motivation | Arteriosclerosis | Atorvastatin | Cardiovascular diseases | Health risk assessment | Heart diseases | Lipoproteins (high density) | Index Medicus | Abridged Index Medicus | Trial Design
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights